Publications by authors named "Klaus Linz"

Claim this Profile
C
Cebranopadol: A Novel First-in-Class Potent Analgesic Acting via NOP and Opioid Receptors.
Thomas M Tzschentke, Klaus Linz, Thomas Koch, Thomas Christoph

Handb Exp Pharmacol· July 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inhibition of experimental visceral pain in rodents by cebranopadol.
Klaus Schiene, Wolfgang Schröder, Klaus Linz, Stefanie Frosch, Thomas M Tzschentke

Behav Pharmacol· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Limited potential of cebranopadol to produce opioid-type physical dependence in rodents.
Thomas M Tzschentke, Babette Y Kögel, Stefanie Frosch, Klaus Linz

Addict Biol· September 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nociceptin/orphanin FQ opioid peptide (NOP) receptor and µ-opioid peptide (MOP) receptors both contribute to the anti-hypersensitive effect of cebranopadol in a rat model of arthritic pain.
Klaus Schiene, Wolfgang Schröder, Klaus Linz, Stefanie Frosch, Thomas M Tzschentke

Eur J Pharmacol· August 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quantitative Assessment of Drug Delivery to Tissues and Association with Phospholipidosis: A Case Study with Two Structurally Related Diamines in Development.
Irena Loryan, Edmund Hoppe, Klaus Hansen, Felix Held, Achim Kless, Klaus Linz

Mol Pharm· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Antihyperalgesic, Antiallodynic, and Antinociceptive Effects of Cebranopadol, a Novel Potent Nociceptin/Orphanin FQ and Opioid Receptor Agonist, after Peripheral and Central Administration in Rodent Models of Neuropathic Pain.
Thomas M Tzschentke, Klaus Linz, Stefanie Frosch, Thomas Christoph

Pain Pract· November 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Opioid-type Respiratory Depressant Side Effects of Cebranopadol in Rats Are Limited by Its Nociceptin/Orphanin FQ Peptide Receptor Agonist Activity.
Klaus Linz, Wolfgang Schröder, Stefanie Frosch, Thomas Christoph

Anesthesiology· April 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of Spiro[cyclohexane-dihydropyrano[3,4-b]indole]-amines as Potent NOP and Opioid Receptor Agonists.
Stefan Schunk, Klaus Linz, Sven Frormann, Claudia Hinze, Stefan Oberbörsch

ACS Med Chem Lett· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Discovery of a Potent Analgesic NOP and Opioid Receptor Agonist: Cebranopadol.
Stefan Schunk, Klaus Linz, Claudia Hinze, Sven Frormann, Stefan Oberbörsch

ACS Med Chem Lett· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cebranopadol: a novel potent analgesic nociceptin/orphanin FQ peptide and opioid receptor agonist.
Klaus Linz, Thomas Christoph, Thomas M Tzschentke, Thomas Koch, Klaus Schiene

J Pharmacol Exp Ther· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Differential effects of human ether-a-go-go-related gene (HERG) blocking agents on QT duration variability in conscious dogs.
Johannes Schneider, Renate Hauser, Jens-Otto Andreas, Klaus Linz, Ulrich Jahnel

Eur J Pharmacol· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis